Peptide Comparison
VesilutevsTriptorelin
Tissue-specific dipeptide bioregulator (Glu-Asp) that epigenetically normalizes urogenital function through chromatin remodeling, anti-inflammatory cytokine regulation, and smooth muscle tone restoration in the bladder and prostate
GnRH agonist that helps manage prostate cancer, endometriosis, and early puberty by controlling sex hormones
At a Glance
Quick
comparison
Dose Range
Vesilute
20–40 mg
Triptorelin
0.1 mg–22.5 mg mg
Frequency
Vesilute
Once daily
Triptorelin
Once daily
Administration
Vesilute
Oral (capsule/tablet)
Triptorelin
Intramuscular injection
Cycle Length
Vesilute
12+ weeks
Triptorelin
Ongoing/indefinite
Onset Speed
Vesilute
Gradual (3-4 weeks)
Triptorelin
Moderate (1-2 weeks)
Evidence Level
Vesilute
Moderate human trials (Phase 1-2)
Triptorelin
Strong human trials (Phase 3 or FDA approved)
Efficacy
Benefit
ratings
Muscle
Anti-aging
Inflammation
Hormone Regulation
Cancer Management
Endometriosis Relief
Technical Data
Compound
specifications
Vesilute
Molecular Formula
C9H14N2O7
Molecular Weight
262.2 g/mol
Half-Life
Short plasma half-life typical of dipeptides (minutes); biological effects persist for weeks to months through epigenetic gene regulation; metabolized to constituent amino acids via standard pathways
Bioavailability
High oral bioavailability for a dipeptide — absorbed intact by intestinal peptide transporter PepT1 (SLC15A1); ultra-short structure enables efficient cellular uptake and nuclear penetration
CAS Number
3918-84-1
Triptorelin
Molecular Formula
C64H82N18O13
Molecular Weight
1311.4 g/mol
Half-Life
2-3 hours (free peptide); 2-4 weeks (depot pamoate formulations)
Bioavailability
~100% (intramuscular/subcutaneous injection)
CAS Number
57773-63-4
Protocols
Dosing
tiers
Vesilute
Triptorelin
Applications
Best
suited for
Vesilute
Supporting bladder health and urinary function in aging individuals
Vesilute is particularly well-suited for individuals focused on supporting bladder health and urinary function in aging individuals. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Bioregulatory approach to benign prostatic hyperplasia (BPH) management
Vesilute is particularly well-suited for individuals focused on bioregulatory approach to benign prostatic hyperplasia (bph) management. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Reducing chronic urogenital inflammation through epigenetic mechanisms
Vesilute is particularly well-suited for individuals focused on reducing chronic urogenital inflammation through epigenetic mechanisms. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Complementing standard urological treatments with peptide bioregulator therapy
Vesilute is particularly well-suited for individuals focused on complementing standard urological treatments with peptide bioregulator therapy. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Triptorelin
Managing advanced prostate cancer when combined with other treatments
Triptorelin is particularly well-suited for individuals focused on managing advanced prostate cancer when combined with other treatments. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Relieving severe endometriosis pain and symptoms
Triptorelin is particularly well-suited for individuals focused on relieving severe endometriosis pain and symptoms. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Delaying puberty development in children with early sexual maturation
Triptorelin is particularly well-suited for individuals focused on delaying puberty development in children with early sexual maturation. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Safety Profile
Side
effects
Vesilute
Common
- Mild gastrointestinal discomfort
- Increased urinary frequency initially
- Mild headache
- Minor fatigue
Uncommon
- Injection site irritation
Serious
- No documented serious adverse effects
Triptorelin
Research Status
Safety
& evidence
Vesilute
Evidence Level
Moderate human trials (Phase 1-2)
FDA Status
Research compound
Safety Overview
Vesilute (fibroin-derived peptide from Bombyx mori silk) demonstrates favorable biocompatibility from cosmetic ingredient testing with minimal allergic or irritant potential despite its animal protein origin. Limited systemic absorption occurs topically, confining effects to dermal layers with low risk of systemic toxicity. Silk-derived peptides have been used in cosmetics for >20 years without documented serious adverse events in published literature. Theoretical hypersensitivity risk exists for individuals with silk allergy, though cross-reactivity with purified peptide is low.
Contraindications
- xKnown hypersensitivity to peptide bioregulators or constituent amino acids (glutamic acid, aspartic acid)
- xPregnancy and breastfeeding — insufficient reproductive safety data
- xActive urinary tract infection requiring antibiotic treatment — treat infection first
- xBladder or prostate malignancy — proliferative effects of peptide bioregulators may be contraindicated
Triptorelin
Evidence Level
Strong human trials (Phase 3 or FDA approved)
FDA Status
FDA approved for this use
Safety Overview
Triptorelin (GnRH agonist) has extensive FDA-approved safety data spanning decades for prostate cancer, endometriosis, and precocious puberty indications. Initial testosterone surge upon initiation ("flare reaction") can worsen prostate cancer or spinal cord compression symptoms, requiring careful patient monitoring in first 1-2 weeks and use of androgen antagonists in high-risk patients. Hypogonadal effects including hot flashes, sexual dysfunction, and bone loss develop predictably with chronic GnRH suppression; bone density monitoring is recommended in patients on therapy >6 months.
Contraindications
- xPregnancy (can affect fetal development)
- xUndiagnosed vaginal bleeding
- xKnown hypersensitivity to GnRH agonists
- xSevere untreated depression
- xActive spinal cord compression in prostate cancer (requires urgent decompression)
Decision Guide
Which is
right for you?
Choose Vesilute if...
- Supporting bladder health and urinary function in aging individuals
- Bioregulatory approach to benign prostatic hyperplasia (BPH) management
- Reducing chronic urogenital inflammation through epigenetic mechanisms
- Complementing standard urological treatments with peptide bioregulator therapy
Choose Triptorelin if...
- Managing advanced prostate cancer when combined with other treatments
- Relieving severe endometriosis pain and symptoms
- Delaying puberty development in children with early sexual maturation